 7. Complication of respiratory diseases such as pulmonary infectious diseaseincl. pulmonary tuberculosis, bronchial asthma, lung fibrosis ,interstitial pneumonitis, or bronchiectasis, in which the evaluations of safety and efficacy of GM-CSF therapy are considered as difficult. 